Patents Issued in October 4, 2016
  • Patent number: 9458425
    Abstract: A process for obtaining human derived embryoid bodies (hEB). Human embryonic stem cells are incubated in vitro in a liquid growth medium under conditions in which the cells undergo differentiation, but do not adhere to the walls of the container. The invention also provides hEBs obtained by the process.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 4, 2016
    Assignees: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Joseph Itskovitz-Eldor, Nissim Benvenisty
  • Patent number: 9458426
    Abstract: The present invention relates to compositions and methods for maintaining undifferentiated pluripotent stem cell cultures.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: October 4, 2016
    Assignee: VIACYTE, INC.
    Inventors: Thomas C Schulz, Allan J Robins
  • Patent number: 9458427
    Abstract: A method of inhibiting ?-amyloid (A?) induced neuronal cell death includes administering to a neuronal cell exposed to a neurotoxic amount of A? a therapeutically effective amount of cell penetrating peptide (CPP). The CPP has an amino acid sequence that has at least 80% sequence identity to about 5 to about 41 consecutive amino acids of SEQ ID NO: 1.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: October 4, 2016
    Assignee: Case Western Reserve University
    Inventor: Shigemi Matsuyama
  • Patent number: 9458428
    Abstract: The invention relates to the field of cell culture, specifically, the derivation of retinal pigmented epithelial cells from pluripotent cells. The invention comprises the use of various cell culture medium supplements, medium formulations, and methods of using such medium supplements and formulations, in order to effect the rapid differentiation of pluripotent cells into retinal pigmented epithelial cells with very high yields. The invention further includes cell culture media formulations for the efficient maintenance, propagation, and maturation of cultured retinal pigmented epithelial cells.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 4, 2016
    Assignee: The Regents of the University of California
    Inventors: Dennis Clegg, David Buchholz, Roxanne Croze, Britney Pennington, Peter Coffey, Lyndsay Leach
  • Patent number: 9458429
    Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: October 4, 2016
    Assignees: Pias Corporation, Osaka University
    Inventors: Keiko Kitamura, Yuta Inami, Koichi Nakaoji, Kazuhiko Hamada, Akito Maeda, Tadashi Furumoto, Yasufumi Kaneda, Katsuto Tamai
  • Patent number: 9458430
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method utilizing a CYP26A inhibitor to produce a population of pancreatic endocrine precursor cells.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 4, 2016
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Patent number: 9458431
    Abstract: We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 ?m and 400 ?m, such as about 200 ?m. It may have a cross sectional dimension of between 20 ?m and 30 ?m. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 ?m and about 120 ?m, for example about 65 ?m. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: October 4, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Steve Oh, Shaul Reuveny, Jian Li, William Richard Nicholas Birch
  • Patent number: 9458432
    Abstract: The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 4, 2016
    Assignee: Bell Biosystems, Inc.
    Inventors: Caleb Bell, III, Alexey Bazarov
  • Patent number: 9458433
    Abstract: The invention relates to the production of dense bodies (DB) and to a pharmaceutical composition containing DB.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: October 4, 2016
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Peter Lischka, Christian Sinzger
  • Patent number: 9458434
    Abstract: An object is to provide a novel enzyme that exhibits glucose dehydrogenase activity. Furthermore, another object is to provide a novel method pertaining to enzyme modification. Provided is a mutated enzyme containing an amino acid sequence wherein one or at least two amino acids selected from a group are substituted with another amino acid in the amino acid sequence of a microorganism-derived glucose oxidase.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: October 4, 2016
    Assignee: AMANO ENZYME INC.
    Inventors: Kyoichi Nishio, Satoshi Koikeda
  • Patent number: 9458435
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. A polynucleotide encoding a peroxygenase was isolated from Penicillium chrysogenum.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 4, 2016
    Assignee: Novozymes A/S
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Patent number: 9458436
    Abstract: The present invention relates to a process for the production of polyunsaturated fatty acids in the seed of transgenic plants by introducing, into the organism, nucleic acids which encode polypeptides with a ?3-desaturase, ?12-desaturase, ?6-desaturase, ?6-elongase, ?5-desaturase, ?5-elongase and/or ?4-desaturase activity. The invention furthermore relates to recombinant nucleic acid molecules comprising the nucleic acid sequences which encode the aforementioned polypeptides, either jointly or individually, and transgenic plants which comprise the aforementioned recombinant nucleic acid molecules. Furthermore, the invention relates to the generation of a transgenic plant and to oils, lipids and/or fatty acids with an elevated content of polyunsaturated fatty acids, in particular arachidonic acid, eicosapentaenoic acid and/or docosahexaenoic acid, as the result of the expression of the elongases and desaturases used in the process according to the invention.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: October 4, 2016
    Assignee: BASF Plant Science GmbH
    Inventors: Petra Cirpus, Jörg Bauer, Xiao Qiu, Guohai Wu, Nagamani Datla
  • Patent number: 9458437
    Abstract: Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (z D17) and c-jun N-terminal kinase (JNK). The polypeptides may be conjugated to a delivery and targeting moiety, such as the cell-membrane transduction domain of the HIV-1 Tat protein. There are also provided methods for treating a disease associated with cytotoxicity or excitotoxicity.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 4, 2016
    Assignee: The University of British Columbia
    Inventors: Max S. Cynader, Guang Yang
  • Patent number: 9458438
    Abstract: An isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel sulfotransferase is provided together with a composition which includes the isolated protein. A transgenic organism transformed by a polynucleotide encoding a protein which is at least partially encoded by a novel sulfotransferase is also provided. The invention also includes a process for in-vivo and in-vitro making a sulfated polysaccharide from an unsulfated polysaccharide or increasing the sulfur content of an already sulfated polysaccharide.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: October 4, 2016
    Assignee: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Shoshana Arad, Lena Plesser, Yaakov Weinstein
  • Patent number: 9458439
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 4, 2016
    Assignees: Children's Medical Center Corporation, Institut Pasteur
    Inventors: Andre Choulika, Richard C. Mulligan
  • Patent number: 9458440
    Abstract: The present invention discloses novel polypeptides and enzyme preparations containing them, which enhance the efficiency of the cellulosic degradation even at elevated temperatures. The polypeptides are produced by recombinant technology, and means for their production are described. The novel polypeptides are useful in processing biomass, and in biofuel, starch, textile, detergent, pulp and paper, food, feed or beverage industries. They may also be used e.g. in cleaning the interior of a dishwashing machine or for biofinishing or biostoning. The novel polypeptides are also useful in animal feed.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: October 4, 2016
    Assignee: Roal Oy
    Inventors: Susanna Makinen, Kari Juntunen, Alexandra Komander, Kim Langfelder, Jari Vehmaanpera, Terhi Puranen
  • Patent number: 9458441
    Abstract: The present invention relates to isolated polypeptides having xanthan degrading activity, catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 4, 2016
    Assignee: Novozymes A/S
    Inventors: Dorotea Raventos Segura, Peter Fischer Halin, Lars Anderson, Martin Simon Borchert, Leigh Murphy, Astrid Boisen, Lorena G. Palmen, Kenneth Jensen, Carsten Sjoeholm, Tine Hoff, Charlotte Blom, Anders Viksoe-Nielsen
  • Patent number: 9458442
    Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: October 4, 2016
    Assignee: Halozyme, Inc.
    Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
  • Patent number: 9458443
    Abstract: The invention discloses cellulase enzymes with optimized properties for processing of cellulose- and lignocellulose-containing substrates. In particular, cellobiohydrolase enzymes with preferred characteristics are disclosed. The present invention provides fusion, insertion, deletion and/or substitution variants of such enzymes. Enzyme variants have enhanced thermostability, proteolytic stability, specific activity and/or stability at extreme pH. Nucleic acid molecules encoding said enzymes, a composition comprising said enzymes, a method for preparation, and the use for cellulose processing and/or for the production of biofuels are disclosed.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: October 4, 2016
    Assignee: SUD-CHEMIE IP GMBH & CO. KG
    Inventors: Ulrich Kettling, Christoph Reisinger, Thomas Brück, Andre Koltermann, Jochen Gerlach, Isabel Unterstrasser, Lutz Röcher, Markus Rarbach, Jörg Claren, Andreas Kohl, Jan Carsten Pieck, Dominik Schlosser
  • Patent number: 9458444
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 4, 2016
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 9458445
    Abstract: The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides in e.g. animal feed and detergents.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: October 4, 2016
    Assignee: Novozymes A/S
    Inventors: Carsten Sjoeholm, Peter Rahbek Oestergaard, Tine Hoff, Robert Piotr Olinski
  • Patent number: 9458446
    Abstract: The present invention relates to polypeptides having endopeptidase activity and to methods of producing and using the polypeptides. The invention also relates to methods of making a food protein hydrolysate using a trypsin-like endopeptidase derived from a bacterium.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: October 4, 2016
    Assignee: NOVOZYMES A/S
    Inventors: Peter Rahbek Oestergaard, Carsten P. Sonksen, Tine Hoff, Gitte B. Lynglev
  • Patent number: 9458447
    Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: October 4, 2016
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
  • Patent number: 9458448
    Abstract: A method for manufacturing single enzyme nanoparticles through silica encapsulation according to the present disclosure does not include a surface functionalization process and a polymerization process during the synthesis, and reaction conditions are mild. Thus, the method is appropriate for a large scale production.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: October 4, 2016
    Assignee: Korea University Research and Business Foundation
    Inventors: Jungbae Kim, Sung-Gil Hong, Byoungsoo Lee
  • Patent number: 9458449
    Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: October 4, 2016
    Assignee: New York University
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Patent number: 9458450
    Abstract: A system having improved trapping force for acoustophoresis is described where the trapping force is improved by manipulation of the frequency of the ultrasonic transducer. The transducer includes a ceramic crystal. The crystal may be directly exposed to fluid flow. The crystal may be air backed, resulting in a higher Q factor.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 4, 2016
    Assignee: FloDesign Sonics, Inc.
    Inventors: Bart Lipkens, Jason Dionne, Walter M. Presz, Jr., Thomas J. Kennedy, III
  • Patent number: 9458451
    Abstract: A receptacle having a plurality of interconnected chambers arranged to permit multiple process steps or processes to be performed independently or simultaneously. The receptacles are manufactured to separate liquid from dried reagents and to maintain the stability of the dried reagents. An immiscible liquid, such as an oil, is included to control loading of process materials, facilitate mixing and reconstitution of dried reagents, limit evaporation, control heating of reaction materials, concentrate solid support materials to prevent clogging of fluid connections, provide minimum volumes for fluid transfers, and to prevent process materials from sticking to chamber surfaces. The receptacles can be adapted for use in systems having a processing instrument that includes an actuator system for selectively moving fluid substances between chambers and a detector. The actuator system can be arranged to concentrate an analyte present in a sample.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: October 4, 2016
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Robert E. Heinz, Haitao Li
  • Patent number: 9458452
    Abstract: The invention relates to a chromatographic device for isolating and/or purifying double-stranded nucleic acids, preferably double-stranded DNA, from a mixture of such nucleic acids with single-stranded nucleic acids, oligonucleotides, mononucleotides, salts and/or other such impurities. The invention also relates to a method for chromatographically isolating and/or purifying same, and to a kit for this purpose.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: October 4, 2016
    Assignee: QIAGEN GmbH
    Inventors: Thorsten Singer, Holger Wedler
  • Patent number: 9458453
    Abstract: The presently disclosed subject matter relates to modified Kunkel mutagenesis methods that use a thermostable DNA polymerase and a thermostable DNA ligase.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: October 4, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Elad Firnberg, Marc Alan Ostermeier
  • Patent number: 9458454
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD-2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporter's capacity to transport lipid IVA or in membrane protein YhjD. One or more genes (e.g., lpxL, lpxM, pagP, lpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 4, 2016
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David Bramhill, Uwe Mamat
  • Patent number: 9458455
    Abstract: A high efficiency plant expression promoter from Capsicum annuum serine hydroxymethyl transferase gene and uses thereof. This high efficiency plant expression promoter and 5?-untranslated region (5?-UTR) from Capsicum annuum serine hydroxymethyl transferase gene, a high efficiency plant expression vector having the same, a plant transformed with the vector, a process for high efficiency expression of a foreign gene by using the vector and a transformed plant which expresses with high efficiency a foreign gene based on the process and seeds of the transformed plant.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: October 4, 2016
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Do Il Choi, Sang Hyeob Lee, Young Hee Joung
  • Patent number: 9458456
    Abstract: Some embodiments of the present technology relate to methods and compositions for the diagnosis and treatment of cancer. Some embodiments include methods and compositions for the diagnosis and treatment of castration-resistant prostate cancer. Some embodiments include methods and compositions for the diagnosis and treatment of pancreatic cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 4, 2016
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Ajay Pratap Singh, Sanjeev Srivastava, Seema Singh
  • Patent number: 9458457
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 4, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 9458458
    Abstract: This disclosure relates to manipulating microRNA for the management of neurological disorders and compositions related thereto. In certain embodiments, the disclosure contemplates inhibition of miR324 or miR324-5p, e.g., the use of nucleobase polymers for antisense disruptions or RNA interference of miR-324 expression or for miR324-5p binding in order to increase Kv4.2 expression. In certain embodiments, the disclosure relates to methods of treating or preventing a neurological disease or condition comprising administering an effective amount of an inhibitor to a subject in need thereto.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: October 4, 2016
    Assignee: Emory University
    Inventors: Gary J. Bassell, Xiaodi Yao, Christina Gross
  • Patent number: 9458459
    Abstract: This invention provides a method for enhancing utrophin protein production in a cell by inhibiting an utrophin microRNA molecule. Moreover, the invention provides that methods for enhancing utrophin protein production in a muscle cell are used for treating a muscular dystrophy and/or other myopathies.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: October 4, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Catherine Moorwood, Utpal Basu, Gopal Patel, Olga Lozynska, Tejvir S. Khurana
  • Patent number: 9458460
    Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: October 4, 2016
    Assignees: National University of Singapore, Singapore Health Services Pte Ltd.
    Inventors: Patrick Tan, Tatiana Ivanova
  • Patent number: 9458461
    Abstract: The present invention is related to an siRNA comprising an antisense strand and a sense strand, wherein all or a portion of said antisense strand comprises an antisense duplex region, wherein all or a portion of said sense strand comprises a sense duplex region, wherein said antisense duplex region is at least partially complementary to said sense duplex region, wherein said siRNA comprises a duplex region consisting of said antisense duplex region and said sense duplex region, and wherein: a) said antisense strand comprises a nucleotide sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 68, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102 or 104; or b) said antisense strand comprises an antisense duplex region, all or a portion of which, is complementary to a portion of SEQ ID NO: 1 or 70.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 4, 2016
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Ansgar Santel, Jörg Kaufmann, Martin Witzenrath
  • Patent number: 9458462
    Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: October 4, 2016
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Anna I. Mandinova, Sam W. Lee, Victor A. Neel
  • Patent number: 9458463
    Abstract: The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 4, 2016
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Mathias Falcenberg, Axel Ullrich
  • Patent number: 9458464
    Abstract: The present invention relates to the field of neurology. More specifically, the present invention provides methods and composition useful for treating neuropathic pain. In a specific embodiment, the present invention provides a recombinant Kcna2 sense fragment. In another embodiment, the present invention provides a method of treating neuropathic pain comprising the step of administering a composition comprising a recombinant Kcna2 sense fragment.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: October 4, 2016
    Assignee: The Johns Hopkins University
    Inventor: Yuanxiang Tao
  • Patent number: 9458465
    Abstract: Disclosed herein are compositions and methods for repairing cell membranes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the repair of cell membranes. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with cell membrane damage.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: October 4, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Noah Weisleder, Chuanxi Cai, Jianjie Ma
  • Patent number: 9458466
    Abstract: A translational control method using an RNA-protein interaction motif is provided. The method comprises a step of introducing an mRNA having: a 5?UTR regulation structure comprising: (1) a cap structure at the 5? terminus, (2) a spacer positioned on the 3? side of the cap structure, and (3) one or more RNA motifs positioned on the 3? side of the spacer, which comprises an RNA-protein interaction motif-derived nucleotide sequence or a variant thereof; and a nucleotide sequence encoding a target protein gene on the 3? side of the 5?UTR regulation structure, into a cell in the presence of a protein specifically binding to the RNA motifs, wherein a translational level is decreased as the number of bases of the spacer decreases, and the translational level is decreased as the number of the RNA motifs increases.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: October 4, 2016
    Assignee: Kyoto University
    Inventors: Hirohide Saito, Kei Endo, Tan Inoue
  • Patent number: 9458467
    Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: October 4, 2016
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
  • Patent number: 9458468
    Abstract: A bacterial host cell is disclosed including at least two copies of an amplification unit in its genome, the amplification unit including: i) at least one copy of a gene of interest, and ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of the conditionally essential gene, and wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; methods for producing a protein using the cell of the invention, and methods for constructing the cell of the invention.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: October 4, 2016
    Assignee: Novozymes A/S
    Inventors: Carsten Olsen, Michael Dolberg Rasmussen
  • Patent number: 9458469
    Abstract: The present invention relates to a method for obtaining improved strains of yeast by integrating at least one gene of interest in a region linked to a sex expression locus, followed by cross-breeding. The present invention also relates to gene integration cassettes and to vectors that can be used in the context of said method. The present invention also relates to improved strains of yeast obtained by the above method, the derived strains of yeast and the yeasts obtained by culturing said strains of yeast.
    Type: Grant
    Filed: May 27, 2013
    Date of Patent: October 4, 2016
    Assignee: LESAFFRE ET COMPAGNIE
    Inventors: Thomas Desfougeres, Georges Pignede
  • Patent number: 9458470
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: October 4, 2016
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Patent number: 9458471
    Abstract: The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type. A quorum sensing systems that regulates the expression of cell fate regulators is introduced into mammalian host cells, such as stem cells. The quorum sensing systems generally comprises vectors that express the components of a bacterial quorum sensing pathway, including proteins which catalyze the synthesis of an autoinducer and a gene encoding a regulatory partner of the autoinducer, and vectors in which genes encoding cell fate regulators are operably linked to a promoter induced by the autoinducer/regulatory partner complex.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 4, 2016
    Assignee: The Trustees of Princeton University
    Inventors: Ron Weiss, Ihor Lemischka, Priscilla Purnick, Christoph Schaniel, Miles Miller, Patrick Guye
  • Patent number: 9458472
    Abstract: In its various embodiments, the invention provides, first, a composition comprising a vector for transfecting a cell. The vector comprises a first nucleic acid encoding an antisense agent having thereon an RNA interference target for a transcript of a gene endogenous to the cell. The vector further comprises a second nucleic acid that encodes a cell-killing agent. The second nucleic acid further comprises a sequence of nucleotides transcribable into a non-coding region of a transcript of the second nucleic acid, such that the non-coding region becomes an RNA interference target for the antisense agent. In the transfected cell, the vector operates to interfere with the expression of the cell-killing agent unless and until the vector senses certain endogenous gene signals, whereupon it releases the cell-killing agent.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: October 4, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Ron Weiss, Priscilla E. M. Purnick, Caroline DeHart, Jon Monk, Aparna Swaminathan
  • Patent number: 9458473
    Abstract: The present invention relates to the field of viral gene therapy. More specifically, the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP (SEQ ID NO:45), wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP (SEQ ID NO:10) inserted into the HI-loop of adenovirus fiber protein.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: October 4, 2016
    Assignee: The Johns Hopkins University
    Inventors: Shawn Edward Lupold, Ping Wu, Ronald Rodriguez
  • Patent number: 9458474
    Abstract: A method for producing hydrogen from organic material. Organic material and hydrogen-producing microorganisms are provided in a completely mixed bioreactor for breaking down the organic material into H2, CO2, fatty acids, and alcohols. H2, CO2, and a first liquid effluent are recovered from the completely mixed bioreactor. The first liquid effluent includes hydrogen-producing microorganisms, fatty acids, and alcohols. The first liquid effluent is provided into a gravity settler for separating the first liquid effluent into a concentrated biomass (including hydrogen-producing microorganisms) and a second liquid effluent (including at least a portion of the fatty acids and the alcohols). The concentrated biomass is provided into the completely mixed bioreactor. An input voltage is applied to at least one of the completely mixed bioreactor and the gravity settler for facilitating an electrohydrogenesis process therein.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: October 4, 2016
    Assignee: GREENFIELD SPECIALTY ALCOHOLS INC.
    Inventor: Hisham Mohamed Hafez